Ketamine Therapy for depression

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its proprietary R-ketamine compound PCN-101. See Also: Breaking Ground In Prevention &...

Myconic Capital Corp. (CSE: MEDI) agreed to buy Mindscape Ketamine & Infusions Therapy PLLC for $175,000. The investment company, which previously operating as Auralite Investments Inc. and has holdings in cannabis, signed a letter of intent to acquire all shares of Mindscape for...